Skip to content

Glaukos

US · GKOS #1500 by market cap Listed 2015
237.31 -0.79 -0.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 20.28 Expensive vs history 100th percentile
5-year average 8.05 · #123 of 126 in Medical Devices
P/E ratio -83.29 Cheap vs history 1st percentile
5-year average -43.48 · forward 209.61
P/S ratio 21.07 Expensive vs history 93rd percentile
5-year average 13.03 · forward 15.16 · #126 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Glaukos (GKOS) 14.05B -80.44 19.58 0.00%
Abbott Laboratories (ABT) 178.39B 38.29 3.50 2.41%
Medtronic (MDT) 127.84B 24.62 2.54 2.85%
Stryker Corp (SYK) 118.01B 33.01 5.03 1.14%
Boston Scientific (BSX) 60.85B 17.71 2.37 0.00%
Edwards Lifesciences (EW) 58.56B 57.54 5.39 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value194.97 Economic moatNone UncertaintyHigh

Trading 17.8% above Morningstar's fair value estimate.

Fair value

Glaukos Corp earns a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 26% premium over our quantitative fair value estimate of $194.97 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's lack of profitability undermines our valuation estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of -0.1%, which sits in the bottom 30% compared with global peers. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are expensive.

The firm's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 5.4%, for example, falls in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Glaukos discussion 0 comments

Add a comment